Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206414 · ClinicalTrials.gov registry record · Phase 2
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer
A Phase 2 study, sponsored by Baylor Breast Care Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00206414: Clinical Trial Phase 2 study, sponsored by Baylor Breast Care Center.
NCT00206414 is a Phase 2 study that was terminated before completion, run by Baylor Breast Care Center. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206414, a Phase 2 study, was terminated before completion, sponsored by Baylor Breast Care Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The investigators want to know if combining Arimidex and Faslodex with Iressa will be an effective treatment for breast cancer. They also want to know, using special tests on the tumor, the changes that occur with the treatment so they can try to improve their treatment for breast cancer in the future.
Interventions
- DRUG Iressa Day 1 given with Arimidex and Faslodex
- DRUG Iressa Day 21 given with Arimidex and Faslodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2003-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Why NCT00206414 stopped before completion
NCT00206414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Iressa Day 1 given with Arimidex and Faslodex is the first listed.
NCT00206414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206414 about?
NCT00206414 is a clinical study titled "Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer". The investigators want to know if combining Arimidex and Faslodex with Iressa will be an effective treatment for breast cancer. They also want to know, using special tests on the tumor, the changes that occur with the treatment so they can try to improve their treatment for breast cancer in the futu...
What is the current status of trial NCT00206414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2003-01. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00206414?
The interventions under investigation include: Iressa Day 1 given with Arimidex and Faslodex (DRUG), Iressa Day 21 given with Arimidex and Faslodex (DRUG).
Who is sponsoring clinical trial NCT00206414?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206414's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia